Active Quantitative Equity

Time to Re-Evaluate Health Care Stocks

- Political uncertainty sparked a selloff in US health care stocks in March and April.
- Our multi-dimensional analysis of return and risk suggests that reducing our position size in this sector may be warranted.
- Nevertheless, fundamental drivers of performance remain strong in the sector, and we will likely retain some exposure to pharmaceuticals and health care providers.

In September 2018, we suggested in this commentary that the time was right to explore further opportunities in US health care stocks, particularly in the pharmaceuticals and providers and services segments. Since then, however, political uncertainty has spawned an indiscriminate sell-off in many health care names, beginning in March 2019 and hitting lows around April 17 – even as equity markets continued to grind higher. The key point of uncertainty is whether a change in party power following the 2020 US elections could lead to sweeping health-care reform.

In this month’s commentary, we’ll revisit US health care stocks through the framework of our investment process. Rather than pondering the probability of a given election outcome and considering whether large-scale health care reform is likely to take shape in 18 months’ time – and then attempting to estimate earnings impact based on those probabilities – we rely instead on our well-defined investment processes and discipline to respond to this political uncertainty.

Assessing return and risk
As we outlined in September, our generally positive view of US health care stocks was based on its broad source of secular growth (via an aging population and advances in technology), the availability of value within the sector (selectively, not in aggregate), the improvements in earnings growth across the sector, and its lower variability in earnings (with the exception of biotechnology) compared to other sectors.

The return estimates we create for any stock in the equity market include value and quality metrics, which provide long-term evaluation of fundamental drivers of stock prices. Our return estimates also include measures of market sentiment, which gauge short-term return drivers. Broadly speaking, our analysis suggests that the fundamental drivers of return for US health care stocks remain strong, but sentiment has deteriorated.

1 CFA® is a trademark of the CFA Institute
Fundamental drivers of return – value and quality

By our assessment, fundamental attributes for the underlying health care industries remain the same, or are even more attractive, post-selloff (see Figure 1). Most valuation multiples (measured with respect to, for example, earnings, cash flow or enterprise value) have improved, although there has been a deterioration in capital management among health care providers. Meanwhile, the drivers of internal growth that indicate quality, including margin improvement and debt, remain strong and have improved in many cases. US health care companies have also kept asset growth under control — another sign of good quality. Furthermore, employment growth and other drivers are pointing to continued solid fundamentals for many companies in the sector.

![Figure 1](image_url)

Change in aggregate rank between 31 January 2019 and 30 April 2019.

Based on State Street Global Advisors’ proprietary measures of value, quality and sentiment for US stocks in the Health Care GICS sector.

Legend
- Health Care Providers
- Health Care Equipment
- Pharmaceuticals
- Biotechnology

Using our assessment of fundamental drivers to compare various health care segments, health care providers and services continue to be most preferred, followed by pharmaceuticals (based on valuation) and biotech on (based on quality). Health care equipment is least preferred by these measures, because it is in aggregate much more expensive than other health care segments.

Market sentiment as a driver of return

We take a multi-dimensional view of market sentiment, including price movements, changes to earnings and sales forecasts, hedge fund positioning. By these measures, market sentiment in aggregate has declined across US health care firms, but only with respect to price movements. Earnings forecasts still look strong and are improving in most segments, and hedge fund positioning is very positive in the sector.

It’s also worth noting that, despite this overall decline in sentiment, the health care equipment and pharmaceuticals segments still have strong sentiment indicators, particularly with respect to hedge fund positioning and earnings-forecast improvement, which each provide insight into the aggregate views of informed investors and market observers.

Risk forecasts

In addition to forecasting returns, we believe that it’s important to forecast risk in order to size positions in a risk-aware portfolio. Where expected returns are equal, we prefer companies that bring less volatility to the portfolio over those that bring more volatility.

There are many aspects of portfolio and market volatility: beta estimates, risk models that aggregate risk into stock specific risk, common factor risk, correlations among industries and among countries, and more.

Glossary

Market sentiment - Market sentiment refers to the overall attitude of investors toward a particular security or financial market.

GICS - the acronym for Global Industry Classification Standard
Volatility derived from industry exposure (often called “industry factor risk”) has risen in all the main health care segments (see Figure 2). Within health care providers and pharmaceuticals, the risk derived from idiosyncratic or stock-specific characteristics has also risen.

**The bottom line**

Based on our proprietary measures, health care stocks have experienced a decline in expected return and an increase in expected risk in recent months (see Figure 3). Nevertheless, fundamental drivers of performance remain strong in the sector, and according to our measures, health care providers and pharmaceuticals are still among the more attractive industries across the US equity market. We believe that the change in return and risk may warrant a reduced position size, but at these levels, we will likely retain some exposure to the pharmaceutical and health care provider segments.

To reach this conclusion, we focus on measurable and tangible aspects of our investment process, which is designed to respond to changes in market sentiment as they arise for any reason. We believe this approach allows us to make better investment decisions than the alternative – spending our time arbitrarily assigning probabilities to highly uncertain future political events and their subsequent outcomes.
Marketing communication

State Street Global Advisors Worldwide Entities

Abu Dhabi: State Street Global Advisors Limited, Middle East Branch, 42801, 28, Al Khaleem Tower, Abu Dhabi Global Market Square, Al Maryah Island, Abu Dhabi, United Arab Emirates. Regulated by the Financial Services Regulatory Authority, T: +971 2 245 9000. Australia: State Street Global Advisors, Australia, Limited (ABN 42 003 914 225) is the holder of an Australian Financial Services Licence (AFSL Number 238276), Registered office: Level 17, 420 George Street, Sydney, NSW 2000, Australia T: +61 9240-7611. Belgium: State Street Global Advisors Ireland Limited, Brussels Branch, Chaussée de La Hulpe 120, 1000 Brussels, Belgium. T: 32 2 663 2036. F: 32 2 672 2077. is a branch of State Street Global Advisors Ireland Limited, registered in Ireland with company number 145221, authorised and regulated by the Central Bank of Ireland, and whose registered office is at 78 Sir John Rogerson’s Quay, Dublin 2, Ireland: State Street Global Advisors Ireland Limited is regulated by the Central Bank of Ireland. Registered office address 78 Sir John Rogerson’s Quay, Dublin 2, Registered Number: 145221. T: +353 (0) 1 766 3000. F: +353 (0) 1 766 3300. Italy: State Street Global Advisors Ireland Limited, Milan Branch (Sede Secondaria di Milano) is a branch of State Street Global Advisors Ireland Limited, registered in Ireland with company number 145221, authorised and regulated by the Central Bank of Ireland, and whose registered office is at 78 Sir John Rogerson’s Quay, Dublin 2. State Street Global Advisors Ireland Limited, Milan Branch (Sede Secondaria di Milano), is registered in Italy with company number 145221, directed at professional clients (this includes eligible counterparties) who are deemed both knowledgeable and experienced in matters relating to investments. The products and services to which this communication relates are only available to such persons and persons of any other description (including retail clients) are not entitled to rely on this communication. Investing involves risk including the risk of loss of principal. Quantitative investing assumes that future performance of a security relative to other securities may be predicted based on historical economic and financial factors, however, any errors in a model used might not be detected until the fund has sustained a loss or reduced performance related to such errors. The views expressed are the views of Olivia Engel only through April 30, 2019 and are subject to change based on market and other conditions. This document contains certain statements that may be deemed forward-looking statements. Please note that any such statements are not guarantees of any future performance and actual results or developments may differ materially from those projected.

For use in Switzerland. The information provided does not constitute investment advice and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any investor’s particular investment objectives, strategies, tax status or investment horizon. You should consult your tax and financial advisor.

All information has been obtained from sources believed to be reliable, but its accuracy is not guaranteed. There is no representation or warranty as to the current accuracy, reliability or completeness of, nor liability for, decisions based on such information.

Disclosure

The information provided does not constitute investment advice and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any investor’s particular investment objectives, strategies, tax status or investment horizon. You should consult your tax and financial advisor.

All information has been obtained from sources believed to be reliable, but its accuracy is not guaranteed. There is no representation or warranty as to the current accuracy, reliability or completeness of, nor liability for, decisions based on such information.

The views expressed are the views of Olivia Engel only through April 30, 2019 and are subject to change based on market and other conditions. This document contains certain statements that may be deemed forward-looking statements. Please note that any such statements are not guarantees of any future performance and actual results or developments may differ materially from those projected.

Investing involves risk including the risk of loss of principal. Quantitative investing assumes that future performance of a security relative to other securities may be predicted based on historical economic and financial factors, however, any errors in a model used might not be detected until the fund has sustained a loss or reduced performance related to such errors.

The MSCI World Index, MSCI World ex US and the MSCI US Index are trademarks of MSCI Inc. MSCI indices are the exclusive property of MSCI Inc. ("MSCI"). MSCI and the MSCI index names are service mark(s) of MSCI or its affiliates and have been licensed for use for certain purposes by State Street Global Advisors (“SSGA”). The financial securities referred to herein are not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such financial securities. No purchaser, seller or holder of this product, or any other person or entity, should use or refer to any MSCI trade name, trademark or service mark to sponsor, endorse, market or promote this product without first contacting MSCI to determine whether MSCI’s permission is required. Under no circumstances may any person or entity claim any affiliation with MSCI without the prior written permission of MSCI. The trademarks and service marks referenced herein are the property of their respective owners. Third party data providers make no warranties or representations of any kind relating to the accuracy, completeness or timeliness of the data and have no liability for damages of any kind relating to the use of such data.

The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without SSGA’s express written consent. For use in Australia. Issued by State Street Global Advisors, Australia, Limited (AFSL Number 238276, ABN 42 003 914 225) ("SSGA Australia"), Registered office: Level 17, 420 George Street, Sydney, NSW 2000, Australia T: +61 9240 7600 Web: ssga.com. This communication is directed at professional clients (this includes eligible counterparties) who are deemed both knowledgeable and experienced in matters relating to investments. The products and services to which this communication relates are only available to such persons and persons of any other description (including retail clients) should not rely on this communication.

For use in Switzerland. The information provided does not constitute investment advice and it should not be relied on as such.